SCHEMBL6992051

SCHEMBL6992051

CCOC(=O)c1c(N)sc2cc(OC)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.57
MAPT P10636 9/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALOX15 P16050 3/20 0.55
USP2 O75604 1/20 0.55
ALDH1A1 P00352 8/20 0.54
HPGD P15428 6/20 0.54
GAA P10253 3/20 0.54
PRKCZ Q05513 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TSHR P16473 3/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 5/20 0.51
HSD17B10 Q99714 3/20 0.51
NPSR1 Q6W5P4 3/20 0.51
TP53 P04637 1/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6996573 0.86 MAPT (0.57) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL24683238 0.85 MAPT (0.57) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL2308619 0.84 MAPT (0.60) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL14539618 0.84 MAPT (0.54) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL30701714 0.83 KDM4E (0.46) GRM6MAPTMEN1KMT2AALDH1A1
SCHEMBL26963145 0.83 KDM4E (0.46) GRM6MAPTMEN1KMT2AALDH1A1
SCHEMBL8203054 0.82 MAPT (0.52) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL2472766 0.81 HPGD (0.46) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL2307828 0.80 MAPT (0.60) GRM6MAPTMEN1KMT2AALOX15
SCHEMBL6995771 0.80 SMN1; SMN2 (0.50) GRM6MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174629-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY OTCPHARM JSC (RU) 2024-05-30 US disclosed
EP-4293017-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY Otcpharm JSC (RU) 2023-12-20 EP disclosed
CN-117222630-A 2-acetamido-6-hydroxy-benzothiophene derivatives having antiviral activity OTC制药公司(JSC) 2023-12-12 CN disclosed
WO-2022173329-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY Акционерное общество "Отисифарм" 2022-08-18 WO disclosed
WO-2022173329-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY Акционерное общество "Отисифарм" 2022-08-18 WO disclosed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT GRM6 347/4885MAPT 15/4885MEN1 1756/4885
US-20240174629-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY ACE2, ACE, EIF2AK2 GRM6 3375/4885MAPT 1064/4885MEN1 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.